



**University of
Zurich**^{UZH}

**Zurich Open Repository and
Archive**

University of Zurich
University Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch

Year: 2018

Adipose tissue macrophage polarization in cardiovascular disease

Geiger, Martin ; Stein, Sokrates

DOI: <https://doi.org/10.1177/2047487317746249>

Posted at the Zurich Open Repository and Archive, University of Zurich

ZORA URL: <https://doi.org/10.5167/uzh-168921>

Journal Article

Accepted Version

Originally published at:

Geiger, Martin; Stein, Sokrates (2018). Adipose tissue macrophage polarization in cardiovascular disease. European Journal of Preventive Cardiology, 25(3):325-327.

DOI: <https://doi.org/10.1177/2047487317746249>

Adipose tissue macrophage polarization in cardiovascular disease

Martin Geiger¹ and Sokrates Stein²

¹Department of Vascular Diseases, School of Medical Sciences, State University of Campinas
Campinas, SP, Brazil

²Center for Molecular Cardiology, University of Zurich, Schlieren, Switzerland

Keywords: Adipose tissue macrophage, macrophage polarization, subcutaneous adipose tissue, visceral adipose tissue, cardiovascular disease, peripheral artery disease, flow cytometry, phagocytic, pro-inflammatory, anti-inflammatory, transitional macrophages, cardiovascular predictors, sex, age, hypercholesterolemia

Word count: ±1374

References: 21

Figure: 1

Address for correspondence

Sokrates Stein, PhD; Center for Molecular Cardiology, University of Zurich, Wagistrasse 12,
8952 Schlieren, Switzerland. E-mail: sokrates.stein@uzh.ch. Phone number: +41-44-
6355097.

Of adipocytes and macrophages

Although a link between body weight, obesity and cardiovascular risk is generally accepted, the right way to assess and correlate abdominal fat content to cardiovascular risk factors and mortality rates is still being analyzed and debated in the scientific field^{1, 2}. Nonetheless, epidemiological studies revealed that abdominal obesity is positively correlated with various cardiovascular risk factors, including systolic blood pressure and triglycerides levels, in adult man and woman as well as in obese children³⁻⁶. Moreover, recent studies using computed tomography measured radiodensity demonstrated that the density and hence quality of a specific adipose tissue may be more informative and sensitive to predict cardiovascular risk compared to fat volume and quantity⁷⁻⁹.

In 1993 the group of Bruce Spiegelman published an important study in which they demonstrated that the adipose tissue directly contributes to systemic inflammation by secreting a pro-inflammatory cytokine, thereby linking obesity to insulin resistance and diabetes¹⁰. Follow up studies demonstrated that the adipose tissue plays important functions in metabolism and inflammation via secretion of various adipokines, including hormones and inflammatory cytokines. In 2003 two different groups showed that a large contribution of the inflammatory state in adipose tissue is attributable to adipose tissue macrophages (ATMs)^{11, 12}.

Macrophage polarization in adipose tissue

ATMs derive from blood monocytes, and likely infiltrate the adipose tissue as part on an inflammatory response¹³. Depending on the immune response and environment, macrophages can polarize into different subtypes, ranging from pro-inflammatory to anti-inflammatory macrophages¹⁴. This polarization is dependent on the interaction with other immune cells, such as T helper cells, but also affected by dietary stimuli. An interesting study demonstrated that leptin-deficient mast cells switch ATMs from a pro- to an anti-inflammatory polarization without altering T cell differentiation¹⁵. Importantly, dietary cholesterol promotes atherosclerosis and ATM accumulation in atherosclerotic mouse models^{16, 17}. Bile acids can also affect the function of ATMs, and pharmacological activation of a bile acid receptor reduced the expression of chemokines in ATMs and prevented atherosclerosis^{18, 19}.

Adipose tissue macrophage polarization and cardiovascular risk

In a new study Ivana Lesna and colleagues analyzed the association between different ATM populations in subcutaneous (SCAT) and visceral (VAT) white adipose tissues and cardiovascular risk factors (reference). VAT was acquired during cleansing of a kidney, either obtained by transplantation from a living kidney donor or during a peripheral arterial tree reconstruction from patients with peripheral arterial disease. SCAT was acquired from similar sites in both groups.

The ATMs were divided into different polarization groups, ranging from pro- to anti-inflammatory states. In the VAT the authors noted a positive correlation between pro-inflammatory ATMs and age, male sex, and hypercholesterolemia. Transitional ATMs, i.e. macrophages expressing both pro- and anti-inflammatory markers, were also increased in hypercholesterolemia, while the content of anti-inflammatory ATMs was reduced. Importantly, statin treatment reversed the enhanced accumulation of pro-inflammatory and transitional ATMs; which is in line with previous studies demonstrating that statins exerts anti-inflammatory functions in macrophages²⁰⁻²³. Notably, the authors did not observe any changes in ATM populations in the VAT related to obesity. However, more pro-inflammatory and less anti-inflammatory macrophages were observed in SCAT of obese patients (Figure). This is rather surprising since VAT has a stronger association with metabolic risk factors²⁴. However, adipocytes and other immune cells also contribute to the overall effect of adipose tissues on cardiovascular risk.

Future perspective

The clinical relevance of ATMs with regards to cardiovascular disease remains unclear. Most likely these macrophages exert their major cardiovascular effects indirectly via paracrine and endocrine signaling to regulate metabolic and inflammatory processes in other tissues. A recent study demonstrated that ATMs secrete miRNA-containing exosomes, which in turn affect glucose tolerance and insulin sensitivity²⁵. It will be very interesting to determine if the miRNAs secreted by these ATMs also exert direct cardiovascular effects.

Funding

We acknowledge support to SS by the Swiss National Science Foundation (PZOOP3_161521), the Novartis Foundation for medical-biological Research (#16B103), and the Olga-Mayenfisch Foundation.

Conflict of interest

None.

References

1. Chen R, Mody PS, Gupta A, et al. Most important outcomes research papers on body weight, obesity and cardiovascular outcomes. *Circ Cardiovasc Qual Outcomes*. 2013; 6: e48-56.
2. Dore H, de Araujo Goncalves P, Carvalho MS, et al. Body mass index as a predictor of the presence but not the severity of coronary artery disease evaluated by cardiac computed tomography. *Eur J Prev Cardiol*. 2014; 21: 1387-93.
3. Roevers LS, Resende ES, Diniz AL, et al. Abdominal Obesity and Association With Atherosclerosis Risk Factors: The Uberlandia Heart Study. *Medicine (Baltimore)*. 2016; 95: e1357.
4. Reeder BA, Senthilselvan A, Despres JP, et al. The association of cardiovascular disease risk factors with abdominal obesity in Canada. Canadian Heart Health Surveys Research Group. *CMAJ*. 1997; 157 Suppl 1: S39-45.
5. Franks PW, Hanson RL, Knowler WC, Sievers ML, Bennett PH and Looker HC. Childhood obesity, other cardiovascular risk factors, and premature death. *The New England journal of medicine*. 2010; 362: 485-93.
6. Balkau B, Deanfield JE, Despres JP, et al. International Day for the Evaluation of Abdominal Obesity (IDEA): a study of waist circumference, cardiovascular disease, and diabetes mellitus in 168,000 primary care patients in 63 countries. *Circulation*. 2007; 116: 1942-51.
7. Franssens BT, Nathoe HM, Leiner T, van der Graaf Y, Visseren FL and group Ss. Relation between cardiovascular disease risk factors and epicardial adipose tissue density on cardiac computed tomography in patients at high risk of cardiovascular events. *Eur J Prev Cardiol*. 2017; 24: 660-70.
8. Gaborit B and Dutour A. Looking beyond ectopic fat amount: A SMART method to quantify epicardial adipose tissue density. *Eur J Prev Cardiol*. 2017; 24: 657-9.
9. Rosenquist KJ, Pedley A, Massaro JM, et al. Visceral and subcutaneous fat quality and cardiometabolic risk. *JACC Cardiovasc Imaging*. 2013; 6: 762-71.
10. Hotamisligil GS, Shargill NS and Spiegelman BM. Adipose expression of tumor necrosis factor- α : direct role in obesity-linked insulin resistance. *Science*. 1993; 259: 87-91.
11. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL and Ferrante AW, Jr. Obesity is associated with macrophage accumulation in adipose tissue. *J Clin Invest*. 2003; 112: 1796-808.
12. Xu H, Barnes GT, Yang Q, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. *J Clin Invest*. 2003; 112: 1821-30.
13. Curat CA, Miranville A, Sengenès C, et al. From blood monocytes to adipose tissue-resident macrophages: induction of diapedesis by human mature adipocytes. *Diabetes*. 2004; 53: 1285-92.

14. Sica A and Mantovani A. Macrophage plasticity and polarization: in vivo veritas. *J Clin Invest.* 2012; 122: 787-95.
15. Zhou Y, Yu X, Chen H, et al. Leptin Deficiency Shifts Mast Cells toward Anti-Inflammatory Actions and Protects Mice from Obesity and Diabetes by Polarizing M2 Macrophages. *Cell Metab.* 2015; 22: 1045-58.
16. Lohmann C, Schafer N, von Lukowicz T, et al. Atherosclerotic mice exhibit systemic inflammation in periadventitial and visceral adipose tissue, liver, and pancreatic islets. *Atherosclerosis.* 2009; 207: 360-7.
17. Subramanian S, Han CY, Chiba T, et al. Dietary cholesterol worsens adipose tissue macrophage accumulation and atherosclerosis in obese LDL receptor-deficient mice. *Arterioscler Thromb Vasc Biol.* 2008; 28: 685-91.
18. Perino A, Pols TW, Nomura M, Stein S, Pellicciari R and Schoonjans K. TGR5 reduces macrophage migration through mTOR-induced C/EBPbeta differential translation. *J Clin Invest.* 2014; 124: 5424-36.
19. Pols TW, Nomura M, Harach T, et al. TGR5 activation inhibits atherosclerosis by reducing macrophage inflammation and lipid loading. *Cell Metab.* 2011; 14: 747-57.
20. Bea F, Blessing E, Shelley MI, Shultz JM and Rosenfeld ME. Simvastatin inhibits expression of tissue factor in advanced atherosclerotic lesions of apolipoprotein E deficient mice independently of lipid lowering: potential role of simvastatin-mediated inhibition of Egr-1 expression and activation. *Atherosclerosis.* 2003; 167: 187-94.
21. Leung PO, Wang SH, Lu SH, Chou WH, Shiau CY and Chou TC. Simvastatin inhibits pro-inflammatory mediators through induction of heme oxygenase-1 expression in lipopolysaccharide-stimulated RAW264.7 macrophages. *Toxicol Lett.* 2011; 207: 159-66.
22. Shyu KG, Chua SK, Wang BW and Kuan P. Mechanism of inhibitory effect of atorvastatin on resistin expression induced by tumor necrosis factor-alpha in macrophages. *J Biomed Sci.* 2009; 16: 50.
23. Tuomisto TT, Lumivuori H, Kansanen E, et al. Simvastatin has an anti-inflammatory effect on macrophages via upregulation of an atheroprotective transcription factor, Kruppel-like factor 2. *Cardiovasc Res.* 2008; 78: 175-84.
24. Fox CS, Massaro JM, Hoffmann U, et al. Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study. *Circulation.* 2007; 116: 39-48.
25. Ying W, Riopel M, Bandyopadhyay G, et al. Adipose Tissue Macrophage-Derived Exosomal miRNAs Can Modulate In Vivo and In Vitro Insulin Sensitivity. *Cell.* 2017; 171: 372-84 e12.




Figure. Scheme illustrating changes in ATM polarization in different patients. SCAT, subcutaneous adipose tissue; VAT, visceral adipose tissue; parenthesis displays a trend; aged, ≥ 51 years.